Dermatoses

0 original drugs

Novel Drugs

Reformulations

Active Trials

Drug Targets

Dermatoses has 0 FDA-approved novel treatments across 1 drug target. Explore market leaders, treatments by mechanism, the clinical pipeline, and drug targets below.

Phase 3 Readouts Pro

8 active Phase 3 trials with confidence-graded completion dates.

Full calendar →

Q1 2027

MG-K10 Injection (Humanized Monoclonal Antibody)

Shanghai Mabgeek Biotech.Co.Ltd

Estimated · fresh NCT07540442

Q2 2027

Lebrikizumab

Almirall, S.A.

Estimated · fresh NCT06526182

Q1 2029

Amlitelimab

Sanofi

Estimated · fresh NCT05492578

Unlock 5 more readouts with confidence-graded estimates

Upgrade to Pro

Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Dermatoses Treatments by Mechanism

Top 5 mechanisms across 13 industry trials with a known mechanism of action.

See full pipeline →

Interleukin-4 Receptor alpha Antagonist

9 trials 1 active 3 sponsors

Azole Antifungal

1 trials 1 sponsor

Calcineurin/FKBP-12

1 trials 1 sponsor

H1-receptor

1 trials 1 sponsor

Interleukin-12 Antagonist

1 trials 1 sponsor

MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.

Dermatoses Clinical Pipeline by Phase

157 industry-sponsored trials across 68 sponsors

Showing 19 of 19 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Sanofi	dupilumab	Interleukin-4 Receptor alpha Antagonist [EPC]	ACTIVE NOT RECRUITING	2027-04-29	NCT05983068
Sanofi	Dupilumab	Interleukin-4 Receptor alpha Antagonist [EPC]	COMPLETED	2024-01-25	NCT05624112
Sanofi	Dupilumab SAR231893	—	COMPLETED	2022-09-07	NCT04718870
Sanofi	Dupilumab (SAR231893)	—	COMPLETED	2022-06-30	NCT04823130
Galderma R&D	Loceryl Nail Lacquer	—	COMPLETED	2016-09	NCT02705664
Galderma R&D	Loceryl NL	—	COMPLETED	2016-06	NCT02679911
Procter & Gamble Beauty	Investigational OTC Cream	—	COMPLETED	2016-06	NCT02732314
Galderma R&D	Loceryl NL + Cosmetic varnish	—	COMPLETED	2016-01	NCT02321098
Allerderm	Ethylenediamine dihydrochloride allergen patch	—	COMPLETED	2012-08	NCT01798589
Promius Pharma, LLC	—	—	COMPLETED	2011-06	NCT01214434
Stiefel, a GSK Company	clobetasol propionate 0.05%	—	COMPLETED	2011-03-01	NCT01323673
Max Zeller Soehne AG	EPOGAM 1000	—	COMPLETED	2010-10	NCT00878670
Galderma Brasil Ltda.	—	—	COMPLETED	2010-09	NCT01063218
Stiefel, a GSK Company	Ketoconazole	Azole Antifungal [EPC]	COMPLETED	2010-04	NCT00703846
Allerderm	T.R.U.E. Test	—	COMPLETED	2009-10	NCT00795951
Orion Corporation, Orion Pharma	—	—	COMPLETED	2009-03	NCT00846235
Janssen-Cilag Ltd.,Thailand	Tacrolimus	Calcineurin/FKBP-12	COMPLETED	2008-11	NCT01782729
Astellas	Locobase® REPAIR	—	COMPLETED	2008-09	NCT00673725
Organon and Co	Cream (betamethasone diproprionate, clotrimazole, and gentamicin sulfate)	—	TERMINATED	2010-05	NCT00671528

Showing 38 of 38 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Sanofi	Amlitelimab	—	RECRUITING	2027-09-30	NCT06241118
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.	611	—	RECRUITING	2026-06-30	NCT07042126
Almirall, S.A.	Lebrikizumab	—	ACTIVE NOT RECRUITING	2027-04-25	NCT06526182
Sanofi	Amlitelimab	—	ACTIVE NOT RECRUITING	2026-06-29	NCT06407934
Eli Lilly	Lebrikizumab	—	ACTIVE NOT RECRUITING	2026-05-13	NCT06921759
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.	611	—	ACTIVE NOT RECRUITING	2025-10-12	NCT06554847
Shanghai Mabgeek Biotech.Co.Ltd	MG-K10 Injection (Humanized Monoclonal Antibody)	—	NOT YET RECRUITING	2027-01-05	NCT07540442
Pfizer	Abrocitinib 100 mg	—	COMPLETED	2025-12-22	NCT03422822
Sanofi	Amlitelimab	—	COMPLETED	2025-11-25	NCT06181435
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.	611	—	COMPLETED	2025-09-26	NCT06173284
Sanofi	Amlitelimab	—	COMPLETED	2025-08-21	NCT06224348
Sanofi	Amlitelimab	—	COMPLETED	2025-07-23	NCT06130566
Almirall, S.A.	Lebrikizumab	—	COMPLETED	2023-01-30	NCT05149313
Regeneron	dupilumab	Interleukin-4 Receptor alpha Antagonist [EPC]	COMPLETED	2022-08-31	NCT04417894
Eli Lilly	Lebrikizumab	—	COMPLETED	2022-07-31	NCT04760314
Arcutis Biotherapeutics, Inc.	Roflumilast Foam	—	COMPLETED	2022-04-06	NCT04973228
Sanofi	Dupilumab SAR231893	—	COMPLETED	2021-11-12	NCT04183335
Sanofi	Dupilumab SAR231893	—	COMPLETED	2021-08-30	NCT04202679
Regeneron	Dupilumab	Interleukin-4 Receptor alpha Antagonist [EPC]	COMPLETED	2021-07-08	NCT03346434
Pfizer	PF-04965842 100 mg	—	COMPLETED	2020-09-02	NCT03627767
Pfizer	PF-04965842 100 mg	—	COMPLETED	2019-12-27	NCT03720470
Pfizer	PF-04965842 100 mg	—	COMPLETED	2019-08-13	NCT03575871
Regeneron	Dupilumab	Interleukin-4 Receptor alpha Antagonist [EPC]	COMPLETED	2019-06-20	NCT03345914
Pfizer	PF-04965842 100 mg	—	COMPLETED	2019-03-26	NCT03349060
Regeneron	Dupilumab	Interleukin-4 Receptor alpha Antagonist [EPC]	COMPLETED	2018-04-04	NCT03054428
Regeneron	Dupilumab	Interleukin-4 Receptor alpha Antagonist [EPC]	COMPLETED	2015-11	NCT02277743
Regeneron	Dupilumab	Interleukin-4 Receptor alpha Antagonist [EPC]	COMPLETED	2015-10-31	NCT02277769
Pfizer	AN2728 Topical Ointment, 2%	—	COMPLETED	2015-04	NCT02118766
Pfizer	AN2728 Topical Ointment, 2%	—	COMPLETED	2015-04	NCT02118792
Organon and Co	Desloratadine 5 mg	—	COMPLETED	2014-03-08	NCT01916980
Bayer	Butenafine HCl 1% (BAY1896425) - Induction Phase	—	COMPLETED	2013-11-11	NCT04532164
Tanabe Pharma Corporation	Bepotastine besilate	H1-receptor	COMPLETED	2013-11	NCT01840605
Bayer	Butenafine HCl 1% (BAY1896425)	—	COMPLETED	2013-06-28	NCT04531527
Galderma R&D	clobetasol propionate shampoo (4/week) - ketoconazole shampoo (2/week)	—	COMPLETED	2010-02	NCT00862654
Allerderm	T.R.U.E. TEST® Skin Patch Test: Dose Response Allergens	—	COMPLETED	2009-08	NCT00640614
Sanofi	Amlitelimab	—	ENROLLING BY INVITATION	2029-01-22	NCT05492578
Allerderm	Patch Test	—	WITHDRAWN	2013-12	NCT01518348
Azidus Brasil	dexamethasone 0.5 mg and 1.0 mg clemastine cream	—	WITHDRAWN	2010-11	NCT01125761

Showing 67 of 67 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Johnson & Johnson	JNJ-95597528	—	RECRUITING	2026-11-19	NCT07230860
Apollo Therapeutics Ltd	Camoteskimab	—	RECRUITING	2027-10-31	NCT07599813
Aclaris Therapeutics, Inc.	ATI-045	—	ACTIVE NOT RECRUITING	2026-08	NCT07011706
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.	Recombinant Anti-interleukin-4 Receptor Alpha Monoclonal Antibody Injection (611)	—	ACTIVE NOT RECRUITING	2026-08	NCT06324812
Graegis Pharmaceuticals Ltd	GR1014-CG 2.4%	—	ACTIVE NOT RECRUITING	2026-09-30	NCT07192588
Sanofi	Amlitelimab	—	ACTIVE NOT RECRUITING	2031-06-11	NCT05769777
Evommune, Inc.	EVO756	—	ACTIVE NOT RECRUITING	2026-07	NCT07150845
Bio-Thera Solutions	Monoclonal antibody BAT6026	—	ACTIVE NOT RECRUITING	2026-06-01	NCT06094179
Sanofi	Lunsekimig	—	COMPLETED	2026-02-12	NCT06790121
Sanofi	Amlitelimab	—	COMPLETED	2025-10-01	NCT06015308
Apollo Therapeutics Ltd	Camoteskimab	—	COMPLETED	2025-03-26	NCT06436183
Sun Pharmaceutical Industries Limited	SCD-044_Dose 1	—	COMPLETED	2024-11-11	NCT04684485
Formation Bio, Inc.	ASN008	—	COMPLETED	2023-11-27	NCT05870865
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.	611 Q2W	—	COMPLETED	2023-07-10	NCT05544591
Galderma R&D	Nemolizumab	—	COMPLETED	2023-07-07	NCT04365387
Arcutis Biotherapeutics, Inc.	ARQ-154	—	COMPLETED	2022-11-19	NCT04445987
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.	611 150mg	—	COMPLETED	2022-10-21	NCT05641558
Edesa Biotech Inc.	EB01 Cream 0.2%	—	COMPLETED	2022-09-21	NCT03680131
Bristol-Myers Squibb	BMS-986166	—	COMPLETED	2022-08-22	NCT05014438
SCM Lifescience Co., LTD.	SCM-AGH	—	COMPLETED	2022-08-02	NCT04179760
Bristol-Myers Squibb	CC-93538	—	COMPLETED	2022-07-20	NCT04800315
Lutris Pharma Ltd.	LUT014 Gel	—	COMPLETED	2022-06-16	NCT04261387
Pfizer	crisaborole ointment	—	COMPLETED	2021-10-19	NCT04091087
AbbVie	Risankizumab	—	COMPLETED	2020-10-28	NCT03706040
Arcutis Biotherapeutics, Inc.	Roflumilast Foam 0.3%	—	COMPLETED	2020-08-18	NCT04091646
Kymab Limited	KY1005	—	COMPLETED	2020-05-12	NCT03754309
Asana BioSciences	ASN002	—	COMPLETED	2020-04-29	NCT03728504
Boehringer Ingelheim	BI 655130	—	COMPLETED	2020-01-17	NCT03822832
ACO Hud Nordic AB	2% urea/20% glycerol cream	—	COMPLETED	2019-11-29	NCT03901144
Allerderm	Metal Allergen Epicutaneous Patch	—	COMPLETED	2019-07-15	NCT02615249
Pfizer	Crisaborole ointment 2% BID	—	COMPLETED	2018-05-04	NCT03233529
Sun Pharmaceutical Industries, Inc.	DSXS	—	COMPLETED	2017-02-22	NCT02595008
GSK	GSK2894512 1% Cream	—	COMPLETED	2017-01-01	NCT02564055
Vitae Pharmaceuticals, Inc.	VTP-38543	—	COMPLETED	2016-09-09	NCT02655679
Haus Bioceuticals	HAT1 topical cream	—	COMPLETED	2016-06-13	NCT03059693
Allerderm	—	—	COMPLETED	2016-05-24	NCT02028208
Amorepacific Corporation	PAC-14028 cream 0.3%	—	COMPLETED	2014-12	NCT02749383
Janssen Pharmaceutical K.K.	Ustekinumab	Interleukin-12 Antagonist [EPC]	COMPLETED	2014-12	NCT01945086
Pfizer	Tofacitinib ointment 20mg/g	—	COMPLETED	2014-09	NCT02001181
Allerderm	Lyral®	—	COMPLETED	2013-06	NCT02028182
Pfizer	AN2728 Topical Ointment, 2% QD	—	COMPLETED	2013-01	NCT01602341
Medicis Global Service Corporation	Test Product 49778	—	COMPLETED	2013-01	NCT01703793
Pfizer	AN2728 Topical Ointment, 2%	—	COMPLETED	2012-10	NCT01652885
Apeiron Biologics	APN201	—	COMPLETED	2012-05	NCT01513278
Pfizer	AN2728 ointment, 2%	—	COMPLETED	2011-11-11	NCT01301508
GSK	GW870086 2.0%	—	COMPLETED	2011-03-01	NCT01299610
Lytix Biopharma AS	LTX-109	—	COMPLETED	2011-02	NCT01223222
Welichem Biotech Inc.	WBI-1001	—	COMPLETED	2010-10	NCT01098734
Aria Aesthetics Inc.	Topical oxygen	—	COMPLETED	2010-01	NCT00991198
Halozyme Therapeutics	rHuPH20	—	COMPLETED	2009-09-13	NCT00928447
ZARS Pharma Inc.	Triamcinolone Acetonide (TAC) DuraPeel	—	COMPLETED	2009-06	NCT00890968
Allerderm	T.R.U.E. TEST® Skin Patch Test: Dose Response Allergens	—	COMPLETED	2009-03	NCT00640250
Allerderm	TRUE Test allergens Fragrance Mix and Thimerosol	—	COMPLETED	2008-12	NCT00612768
Welichem Biotech Inc.	WBI-1001	—	COMPLETED	2008-06	NCT00837551
Johnson & Johnson	Dupilumab	Interleukin-4 Receptor alpha Antagonist [EPC]	TERMINATED	2026-03-26	NCT06881251
GSK	GSK1070806	—	TERMINATED	2025-07-29	NCT06447506
GSK	GSK1070806	—	TERMINATED	2025-07-23	NCT05999799
Johnson & Johnson	Bermekimab	—	TERMINATED	2022-03-09	NCT04990440
Johnson & Johnson	Bermekimab	—	TERMINATED	2022-02-02	NCT04791319
Arjil Pharmaceuticals LLC	AR100DP1	—	TERMINATED	2021-12-29	NCT04220411
Boehringer Ingelheim	Spesolimab	—	TERMINATED	2021-04-28	NCT04086121
GSK	Mepolizumab 100 mg	—	TERMINATED	2017-12-06	NCT03055195
ProTechSure Scientific, Inc.	Difinsa53	—	TERMINATED	2016-03	NCT02534129
Janssen Pharmaceutical K.K.	JNJ-39758979, 300 mg	—	TERMINATED	2012-02	NCT01497119
MYOR Ltd.	—	—	WITHDRAWN	2021-12	NCT03808532
ProCertus BioPharm, Inc	Norepinephrine	—	WITHDRAWN	2012-05	NCT01544504
AstraZeneca	Roflumilast cream	—	WITHDRAWN	2009-06	NCT00746382

Showing 33 of 33 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Suzhou Suncadia Biopharmaceuticals Co., Ltd.	SHR-1894 Injection	—	RECRUITING	2026-10	NCT07414602
Sinomune Pharmaceutical Co., Ltd	ZYG24002 0.5%	—	RECRUITING	2026-12-31	NCT07404033
Novartis	DCY636	—	RECRUITING	2028-01-27	NCT07604324
Sanofi	Amlitelimab	—	COMPLETED	2025-11-21	NCT06686628
Bristol-Myers Squibb	BMS-986326	—	COMPLETED	2025-11-06	NCT06248814
Merck	MK-6194	—	COMPLETED	2024-05-22	NCT05450198
GSK	GSK1070806	—	COMPLETED	2023-07-12	NCT05590338
GSK	GSK1070806	—	COMPLETED	2022-12-19	NCT04975438
Nektar Therapeutics	LY3471851	—	COMPLETED	2022-06-24	NCT04081350
Eli Lilly	LY3454738	—	COMPLETED	2021-09-07	NCT03750643
Pfizer	PF-07038124 and Vehicle	—	COMPLETED	2020-04-10	NCT04135560
Asana BioSciences	ASN008 TG	—	COMPLETED	2020-03-20	NCT03798561
Pfizer	P3-Fast	—	COMPLETED	2019-12-14	NCT04065633
Pfizer	Period 1 - Day 1: PF-04965842 administered	—	COMPLETED	2018-12-13	NCT03634345
Kyowa Kirin Co., Ltd.	KHK4083	—	COMPLETED	2018-02-07	NCT03096223
Hapten Sciences, Inc.	PDC-APB	—	COMPLETED	2018-01	NCT02700373
Asana BioSciences	ASN002	—	COMPLETED	2017-11-05	NCT03139981
Galapagos NV	MOR106 single ascending doses, intravenous	—	COMPLETED	2017-08-01	NCT02739009
Fresh Tracks Therapeutics, Inc.	BBI-2000	—	COMPLETED	2017-05-24	NCT03089775
GSK	GSK2894512 Cream	—	COMPLETED	2015-12-02	NCT02637206
Fresh Tracks Therapeutics, Inc.	BBI-5000	—	COMPLETED	2015-12	NCT02590289
GSK	GSK2894512 Topical Cream	—	COMPLETED	2015-10-27	NCT02466152
Stiefel, a GSK Company	Combination therapy GSK2894512 Cream A + GSK2894512 Cream B	—	COMPLETED	2015-09-24	NCT02411162
Noveome Biotherapeutics, formerly Stemnion	ST266	—	COMPLETED	2015-07	NCT01714973
Dr. August Wolff GmbH & Co. KG Arzneimittel	0.1% WOL071-007	—	COMPLETED	2015-07	NCT02576093
GSK	—	—	COMPLETED	2013-11-26	NCT01910662
GSK	SB705498	—	COMPLETED	2012-10-04	NCT01673529
Regeneron	REGN668	—	COMPLETED	2012-07	NCT01259323
GSK	GW870086 0.2%	—	COMPLETED	2011-07-07	NCT01381445
GSK	levocetirizine	—	COMPLETED	2008-04-30	NCT02447393
Eli Lilly	LY3844583	—	TERMINATED	2024-01-20	NCT05486208
ProCertus BioPharm, Inc	Norepinephrine	—	TERMINATED	2013-04	NCT01263366
ProCertus BioPharm, Inc	Norepinephrine	—	TERMINATED	2012-02	NCT01367990

Novel Dermatoses Drugs by Company (New molecular entities)

No novel drugs found for this indication.

Reformulations (9 drugs) Click to expand

Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.